Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: PIPELINE LANDSCAPE PART 09: MARKET SEGMENTATION BY PRODUCT • Overview • Comparison by product • Shanchol • DUKORAL • Vaxchora • Market opportunity by product PART 10: SEGMENTATION BY GEOGRAPHY • Overview • Regional comparison • Americas • EMEA • APAC • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market challenges PART 13: MARKET TRENDS • Increasing number of public-private initiatives • Focus on developing countries PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive landscape PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • PaxVax • Sanofi • Valneva PART 16: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Cholera: Overview Exhibit 02: Severe form of cholera Exhibit 03: Major cholera outbreaks 2010-2017 Exhibit 04: Parent market Exhibit 05: Market characteristics Exhibit 06: Global cholera vaccines market: Segmentation Exhibit 07: Market definition: Inclusions and exclusions checklist Exhibit 08: Market size 2017 Exhibit 09: Validation techniques employed for market sizing 2017 Exhibit 10: Global cholera vaccines market 2017-2022 ($ millions) Exhibit 11: Global cholera vaccines market: Year-over-year growth 2018-2022 (%) Exhibit 12: Five forces analysis 2017 Exhibit 13: Five forces analysis 2022 Exhibit 14: Bargaining power of buyers Exhibit 15: Bargaining power of suppliers Exhibit 16: Threat of new entrants Exhibit 17: Threat of substitutes Exhibit 18: Threat of rivalry Exhibit 19: Market condition 2017 Exhibit 20: Pipeline landscape by sponsors or collaborators Exhibit 21: Key clinical trials Exhibit 22: Global cholera vaccines market: Segmentation by product 2017-2022 (% share) Exhibit 23: Comparison by product Exhibit 24: Description of Shanchol Exhibit 25: Global Shanchol market 2017-2022 ($ millions) Exhibit 26: Global Shanchol market: Year-over-year growth 2018-2022 (%) Exhibit 27: Description of DUKORAL Exhibit 28: Global DUKORAL market 2017-2022 ($ millions) Exhibit 29: Global DUKORAL market: Year-over-year growth 2018-2022 (%) Exhibit 30: Global Vaxchora market 2017-2022 ($ millions) Exhibit 31: Global Vaxchora market: Year-over-year growth 2018-2022 (%) Exhibit 32: Market opportunity by product Exhibit 33: Global cholera vaccines market: Segmentation by geography 2017-2022 (% share) Exhibit 34: Regional comparison Exhibit 35: Cholera vaccines market in Americas 2017-2022 ($ millions) Exhibit 36: Cholera vaccines market in Americas: Year-over-year growth 2018-2022 (%) Exhibit 37: Cholera vaccines market 2017-2022 ($ millions) Exhibit 38: Cholera vaccines market in EMEA: Year-over-year growth 2018-2022 (%) Exhibit 39: Cholera vaccines market in APAC 2017-2022 ($ millions) Exhibit 40: Cholera vaccines market in APAC: Year-over-year growth 2018-2022 (%) Exhibit 41: Key leading countries: Prevalence of cholera Exhibit 42: Market opportunity Exhibit 43: Countries with high proportion of population without sanitation 2014 Exhibit 44: Number of departures from US to Asia 2012-2015 Exhibit 45: Departures to top Asian countries from US 2015 Exhibit 46: Initiatives to prevent and manage cholera Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Competitive structure analysis Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: PaxVax: Overview Exhibit 54: PaxVax: Business segments Exhibit 55: PaxVax: Organizational developments Exhibit 56: PaxVax: Geographic focus Exhibit 57: PaxVax: Segment focus Exhibit 58: PaxVax: Key offerings Exhibit 59: PaxVax: Key customers Exhibit 60: Sanofi: Overview Exhibit 61: Sanofi: Business segments Exhibit 62: Sanofi: Organizational developments Exhibit 63: Sanofi: Geographic focus Exhibit 64: Sanofi: Segment focus Exhibit 65: Sanofi: Key offerings Exhibit 66: Sanofi: Key customers Exhibit 67: Valneva: Overview Exhibit 68: Valneva: Business segments Exhibit 69: Valneva: Organizational developments Exhibit 70: Valneva: Geographic focus Exhibit 71: Valneva: Segment focus Exhibit 72: Valneva: Key offerings Exhibit 73: Valneva: Key customers

PaxVax, Sanofi, and Valneva.